Mirabegron

Generic Name
Mirabegron
Brand Names
Myrbetriq, Betmiga
Drug Type
Small Molecule
Chemical Formula
C21H24N4O2S
CAS Number
223673-61-8
Unique Ingredient Identifier
MVR3JL3B2V
Background

Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...

Indication

Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.

Associated Conditions
Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
Associated Therapies
-

Mirabegron Combined With Behavioral Intervention for Overactive Bladder:a Prospective Multicenter Randomized Controlled Clinical Study

Phase 4
Conditions
Interventions
First Posted Date
2022-07-11
Last Posted Date
2022-07-11
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
600
Registration Number
NCT05452434

TReating Incontinence for Underlying Mental and Physical Health

First Posted Date
2022-05-05
Last Posted Date
2024-12-04
Lead Sponsor
University of California, San Francisco
Target Recruit Count
270
Registration Number
NCT05362292
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

Stanford University, Palo Alto, California, United States

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

First Posted Date
2022-01-12
Last Posted Date
2022-01-12
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
180
Registration Number
NCT05188742
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei City, Taiwan

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

First Posted Date
2021-06-01
Last Posted Date
2021-08-10
Lead Sponsor
China Medical University Hospital
Target Recruit Count
50
Registration Number
NCT04909255
Locations
🇨🇳

China Medical University Hospital, Taichung, Taiwan

Activation of Brown Adipose Tissue Metabolism Using Mirabegron

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2021-03-30
Last Posted Date
2024-12-09
Lead Sponsor
Université de Sherbrooke
Target Recruit Count
9
Registration Number
NCT04823442
Locations
🇨🇦

Centre de recherche du CHUS, Sherbrooke, Quebec, Canada

Mirabegron and Physiological Function in Cold Environments

First Posted Date
2021-02-23
Last Posted Date
2024-07-12
Lead Sponsor
Indiana University
Target Recruit Count
30
Registration Number
NCT04766021
Locations
🇺🇸

Indiana University, Bloomington, Indiana, United States

Mechanisms for Activation of Beige Adipose Tissue in Humans

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2020-12-14
Last Posted Date
2023-12-11
Lead Sponsor
Philip Kern
Target Recruit Count
65
Registration Number
NCT04666636
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

First Posted Date
2020-11-24
Last Posted Date
2024-11-14
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
26
Registration Number
NCT04641975
Locations
🇹🇷

Site TR90001, Bursa, Turkey

🇫🇷

Site FR33001, Marseille, France

🇰🇷

Site KR82001, Seoul, Seoul Teugbyeolsi, Korea, Republic of

and more 12 locations

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2020-09-24
Last Posted Date
2024-11-15
Lead Sponsor
Astellas Pharma China, Inc.
Target Recruit Count
249
Registration Number
NCT04562090
Locations
🇨🇳

Site CN86014, Beijing, China

🇨🇳

Site CN86010, Chengdu, China

🇨🇳

Site CN86009, Guangzhou, China

and more 12 locations

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

First Posted Date
2020-08-06
Last Posted Date
2024-11-11
Lead Sponsor
Astellas Pharma China, Inc.
Target Recruit Count
24
Registration Number
NCT04501640
Locations
🇨🇳

Site CN86001, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath